MYLS22 是视神经萎缩 1 的选择性抑制剂。它通过影响 NFkB 活性和血管生成基因表达抑制血管生成，靶向作用于内皮细胞 OPA1 ，减少肿瘤的生长。

MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity.

MYLS22 (10 mg/kg/die;?peritumoral injection;?every 2 days for 14 days) causes the tumor growth curtailed mice

306959-01-3

C24H21N5O2S

443.53

DMSO:83.33 mg/mL (187.88 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years